These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Pharmacovigilance in pharmacy practice]. Duquet N J Pharm Belg; 2011 Dec; (4):97-103. PubMed ID: 22299235 [TBL] [Abstract][Full Text] [Related]
4. Modeling, building and evaluating an ontology for the automatic characterization of adverse drug effects during pharmacovigilance. Duclos C; Soualmia LF; Krivine S; Jamet A; Lillo-Louët A Stud Health Technol Inform; 2010; 160(Pt 2):1005-9. PubMed ID: 20841835 [TBL] [Abstract][Full Text] [Related]
5. [Role of adverse effects of immuno-allergic nature at a Regional Pharmacovigilance Center]. Sorbette F; Conte S; Montastruc JL Therapie; 1992; 47(5):445-6. PubMed ID: 1299998 [No Abstract] [Full Text] [Related]
6. Pharmacovigilance in India: how safe are the new drugs? How sure are we? Joshi SR; Sapatnekar SM J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970 [No Abstract] [Full Text] [Related]
8. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance. Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681 [TBL] [Abstract][Full Text] [Related]
9. European commission consultation on pharmacovigilance. Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839 [No Abstract] [Full Text] [Related]
10. A model for the future conduct of pharmacovigilance. Waller PC; Evans SJ Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844 [TBL] [Abstract][Full Text] [Related]
11. Improving pharmacovigilance in Europe. Moore N; Bégaud B BMJ; 2010 Apr; 340():c1694. PubMed ID: 20385717 [No Abstract] [Full Text] [Related]
12. [Pharmacovigilance: a case of phantom ships and Russian roulette]. Stricker BH Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668 [TBL] [Abstract][Full Text] [Related]
13. The management of adverse drug reactions: from diagnosis to signal. Edwards IR Therapie; 2001; 56(6):727-33. PubMed ID: 11878098 [TBL] [Abstract][Full Text] [Related]
15. Adverse drug reaction reporting--1998. Sutcliffe H CMAJ; 1999 Apr; 160(7):1051, 1055. PubMed ID: 10207351 [No Abstract] [Full Text] [Related]
16. Monitoring for adverse drug events. Kennedy DL; Goldman SA Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003 [No Abstract] [Full Text] [Related]
17. Signal detection in pharmacovigilance: empirical evaluation of data mining tools. Chan KA; Hauben M Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080 [No Abstract] [Full Text] [Related]
18. [Retrospective study of adverse drug reactions in the elderly: experience of regional center for pharmacovigilance]. Bruneau S; Bruhat C; Lagarce L; Lainé-Cessac P Therapie; 2001; 56(6):785-91. PubMed ID: 11878111 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi-Pyrénées region]. Pouget-Zago P; Lapeyre-Mestre M; Bagheri H; Montastruc JL Therapie; 1995; 50(5):459-62. PubMed ID: 8571286 [TBL] [Abstract][Full Text] [Related]
20. [A literature review of adverse drug reaction reports. Adverse drug effects can have genetical background]. Rane A Lakartidningen; 2002 May; 99(20):2266-7. PubMed ID: 12082942 [No Abstract] [Full Text] [Related] [Next] [New Search]